Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guérin therapy - PubMed
3 hours ago
- #Transcriptomics
- #BCG Therapy
- #Bladder Cancer
- High-frequency recurrence (HfR) in non-muscle-invasive bladder cancer (NMIBC) is a significant clinical challenge.
- Current risk models like EORTC, EAU, and UROMOL have limited accuracy in predicting frequent recurrence.
- A 75-gene high-frequency recurrence index (HfRI) was developed using transcriptome data to predict recurrence risk.
- HfRI stratifies patients into high-risk and low-risk groups, showing superior predictive performance compared to existing models.
- HfRI-high patients have significantly higher recurrence rates and reduced recurrence-free survival (RFS).
- The HfRI remains an independent predictor of HfR even in patients treated with BCG therapy.
- Pathway analysis reveals HfRI-high tumors have upregulated cell cycle and DNA replication pathways, and suppressed immune signaling.
- HfRI can identify patients unlikely to benefit from standard BCG treatment, aiding personalized therapy decisions.